Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spruce BiosciencesSPRB -1.05%42 Cash-to-Debt is 12.55 as of Jun. 2026, which is 13% below its 10-year median of 14.37. GuruFocus rates SPRB with a GF Score™ of 42/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,397 Biotechnology companies, Spruce Biosciences ranks better than 57.27% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Spruce Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 12.55.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Spruce Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Spruce Biosciences's Cash-to-Debt or its related term are showing as below:
SPRB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.88 Med: 14.37 Max: No Debt
Current: 12.55
During the past 8 years, Spruce Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.88. And the median was 14.37.
SPRB's Cash-to-Debt is ranked better than 57.27% of 1397
companies
in the Biotechnology industry
Industry Median: 6.78
vs SPRB: 12.55
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Spruce Biosciences Cash-to-Debt Related Terms
Spruce Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Spruce Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Spruce Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spruce Biosciences (SPRB) has a Cash-to-Debt of 12.55 as of Jun. 2026. This is 13% below median its historical median of 14.37. Over the past decade, Spruce Biosciences' Cash-to-Debt has ranged from 0.88 to 10,000.00. According to the industry distribution chart, Spruce Biosciences ranks #597 out of 1397 companies in the Biotechnology industry, placing it in the top 42.7%.
Is Spruce Biosciences' Cash-to-Debt too high?
Spruce Biosciences' current Cash-to-Debt of 12.55 is 13% below median its 10-year median of 14.37. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.78. Spruce Biosciences' value of 12.55 is 85.1% above this industry median. Based on the distribution chart, Spruce Biosciences ranks #597 out of 1397 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spruce Biosciences has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' Cash-to-Debt compare to CDXS and CRBU?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #597 out of 1397 companies for Cash-to-Debt. This puts Spruce Biosciences in the upper half of its industry. The industry median Cash-to-Debt is 6.78. Spruce Biosciences' value of 12.55 is 85.1% above this benchmark. Historically, Spruce Biosciences' own Cash-to-Debt has ranged from 0.88 to 10,000.00 over the past decade. While the company's 10-year median is 14.37 vs. the industry median of 6.78, Spruce Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spruce Biosciences's current Cash-to-Debt of 12.55 is 85.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spruce Biosciences's current Cash-to-Debt is 12.55, which is 13% below median its own 10-year median of 14.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $53.58 — trading 1213.2% above its estimated fair value. The current Cash-to-Debt is 12.55, which is 13% below median its 10-year median of 14.37 and 85.1% above the Biotechnology industry median of 6.78. Spruce Biosciences' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current Cash-to-Debt is 12.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $53.58 is trading 1213.2% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
Cash-to-Debt: 12.55 (13% below median its 10-year median of 14.37)
GF Value™: $4.08 vs. price of $53.58 (1213.2% above fair value)
Industry Position: 85.1% above the Biotechnology median (#597 of 1397)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
42GF Score
Get the complete analysis for SPRB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
